Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNOA 
Sonoma Pharmaceuticals Inc (SNOA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: SNOA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.4
1 Year Target Price $13.4
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.96% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.37M USD | Price to earnings Ratio - | 1Y Target Price 13.4 |
Price to earnings Ratio - | 1Y Target Price 13.4 | ||
Volume (30-day avg) 1 | Beta 1.47 | 52 Weeks Range 1.75 - 6.92 | Updated Date 10/27/2025 |
52 Weeks Range 1.75 - 6.92 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -23.84% | Operating Margin (TTM) -27.27% |
Management Effectiveness
Return on Assets (TTM) -16.06% | Return on Equity (TTM) -78.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3355604 | Price to Sales(TTM) 0.43 |
Enterprise Value 3355604 | Price to Sales(TTM) 0.43 | ||
Enterprise Value to Revenue 0.23 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 1649765 | Shares Floating 1622412 |
Shares Outstanding 1649765 | Shares Floating 1622412 | ||
Percent Insiders 1.22 | Percent Institutions 6.31 |
Upturn AI SWOT
Sonoma Pharmaceuticals Inc
Company Overview
History and Background
Sonoma Pharmaceuticals, Inc. (formerly Oculus Innovative Sciences, Inc.) was founded in 2002. It focuses on developing and commercializing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, dermatology, and eye care. The company has expanded through product development and strategic partnerships.
Core Business Areas
- Wound Care: Developing and marketing products for acute and chronic wound healing, including solutions for burns, surgical wounds, and diabetic ulcers.
- Dermatology: Offering products for skin conditions like acne, eczema, and psoriasis, using HOCl technology for its antimicrobial and anti-inflammatory properties.
- Eye Care: Providing products for ocular health, including eyelid cleansers and solutions for dry eye and blepharitis, leveraging the antimicrobial benefits of HOCl.
Leadership and Structure
Amy Trombly is the CEO. The company has a board of directors and a management team overseeing product development, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Microcyn Rx: A prescription-strength HOCl solution used for wound care and dermatological applications. Market share data is not publicly available, but Microcyn Rx competes with other advanced wound care products from companies like Smith & Nephew and Mu00f6lnlycke Health Care. Revenue from Microcyn Rx is significant to Sonoma's overall sales.
- OCuSoft HypoChlor: An over-the-counter HOCl eyelid cleanser for managing blepharitis and other eyelid conditions. Competitors include We Love Eyes and other eyelid cleanser brands. Revenue contributes a notable portion of Sonoma's consumer product sales.
- Dermacyn Wound Care: An HOCl-based wound care solution sold internationally. It is distributed in various countries and competes with local and global wound care brands.
Market Dynamics
Industry Overview
The wound care and dermatology markets are growing due to factors like an aging population, increasing prevalence of diabetes, and rising awareness of skin health. The eye care market is also expanding with a focus on dry eye and blepharitis treatments.
Positioning
Sonoma Pharmaceuticals is positioned as a developer of innovative HOCl-based products. Its competitive advantage lies in the unique properties of stabilized HOCl, which offers antimicrobial and anti-inflammatory benefits. However, small size makes the company less competitive.
Total Addressable Market (TAM)
The total addressable market for wound care, dermatology, and eye care products is estimated to be in the billions of dollars globally. Sonoma Pharmaceuticals is capturing a small portion of this TAM due to its niche focus and limited resources compared to larger competitors.
Upturn SWOT Analysis
Strengths
- Proprietary HOCl technology
- Established product lines
- Strategic partnerships and distribution agreements
- Effective antimicrobial and anti-inflammatory properties of products
Weaknesses
- Limited financial resources
- Small market share compared to larger competitors
- Dependence on key products
- Variable profitability
Opportunities
- Expanding into new geographic markets
- Developing new products based on HOCl technology
- Acquiring or partnering with other companies
- Increasing awareness of HOCl benefits among healthcare professionals and consumers
Threats
- Competition from larger pharmaceutical and medical device companies
- Regulatory challenges
- Pricing pressures
- Patent expirations
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- Mu00f6lnlycke Health Care (Private)
- Bausch + Lomb (BLCO)
Competitive Landscape
Sonoma Pharmaceuticals competes with much larger companies with greater resources. Its advantage lies in its HOCl technology, but it faces challenges in scaling its operations and competing on price.
Growth Trajectory and Initiatives
Historical Growth: Sonoma's growth has been uneven, with periods of revenue growth followed by declines. This is due to market conditions, regulatory hurdles, and competition.
Future Projections: Analyst estimates vary, but the company is expected to grow as they push sales further.
Recent Initiatives: Focus on expanding distribution partnerships, new product development, and focusing on key brands like Microcyn Rx.
Summary
Sonoma Pharmaceuticals leverages unique HOCl technology in wound, dermatology, and eye care, yet faces challenges due to its small size against larger competitors. They have innovative products and strategic partnerships. Financial performance is uneven, and growth depends on expanding its market presence and effective product commercialization. It must focus on resource optimization and strategic partnerships to remain competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Press Releases, Industry Reports, Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after conducting thorough research and consulting with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonoma Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2007-01-25 | CEO, President & Director Ms. Amy M. Trombly Esq., J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8 | Website https://sonomapharma.com |
Full time employees 8 | Website https://sonomapharma.com | ||
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.